Using Patient-Reported Outcomes to Assess Transthyretin Amyloid Cardiomyopathy Progression in Patients Treated With Disease-Modifying Therapy
- PMID: 40628131
- DOI: 10.1016/j.jchf.2025.102553
Using Patient-Reported Outcomes to Assess Transthyretin Amyloid Cardiomyopathy Progression in Patients Treated With Disease-Modifying Therapy
Keywords: ATTR-CM; EQ-5D-5L; KCCQ; QOL; disease progression.
Conflict of interest statement
Funding Support and Author Disclosures Dr Maurer has received grants from the National Institutes of Health (R01HL139671 and R01AG081582-01); has received consulting income from Eidos, Prothena, Ionis, Alnylam, Novo Nordisk, and Intellia; and has received institutional support in the form of clinical trial funding from Pfizer, Attralus, Ionis, Eidos, Intellia, Alexion, and Alnylam. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
LinkOut - more resources
Full Text Sources
Research Materials
